The Role of PARP Inhibition in Clinical Practice
The Role of PARP Inhibition in Clinical Practice
Prof. Jonathan A. Ledermann, Dr Rebecca Dent, Dr Robert L. Coleman, Prof. Eric Pujade-Lauraine
Accredited e-learning: The Role of PARP inhibition in Clinical Practice
Prof. Jonathan A. Ledermann
Medical Oncologist
UCL Cancer Institute
United Kingdom (UK)
Dr Rebecca Dent
Medical Oncologist
National Cancer Center Singapore
Singapore
Dr Robert L. Coleman
Gynaecologic Oncologist
US Oncology Research
United States (US)
Prof. Eric Pujade-Lauraine
Gynaecologic Oncologist
Hôpital Hôtel-Dieu
France
Prof. Jonathan A. Ledermann
Medical Oncologist
UCL Cancer Institute
United Kingdom (UK)
Prof. Jonathan A. Ledermann has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
AstraZeneca, Clovis, Cristal Therapeutics, Pfizer, Roche and Seattle Genetics.
Dr Rebecca Dent
Medical Oncologist
National Cancer Center Singapore
Singapore
Dr Rebecca Dent has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
AstraZeneca, Eisai, Genentech, Lilly, Merck, Novartis, Pfizer and Roche.
Dr Robert L. Coleman
Gynaecologic Oncologist
US Oncology Research
United States (US)
Dr Robert L. Coleman has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
Amgen, Aravive, ArQuel, Cell Medica, Clovis, Geistlich Pharma, Genetech, GenMab, ImmunoGen, Janssen, Medscape, Merck, Mersana, MoreHealth, OncLive, OncoMed, Physicians Educational Resource, Takeda, Tesaro, TRM Oncology and United Therapeutics.
Prof. Eric Pujade-Lauraine
Gynaecologic Oncologist
Hôpital Hôtel-Dieu
France
Prof. Eric Pujade-Lauraine has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
AstraZeneca, Clovis, Pfizer, Roche and Tesaro.
E-learning |
60 min
|accreditation:
EACCME |
Sep 2021
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
DNA Damage Response (DDR) and PARP inhibitors are promising but complex therapeutic strategies.
Understand why, where and how PARP inhibitors work in clinical practice, and look into the future of targeting DDR with this interactive free to access e-learning course. Designed to support you in selecting the appropriate treatment strategy with PARP inhibitors in the appropriate patient population and to provide the best possible patient care.
This course is endorsed by the Innovative Breast Cancer Research Group (SOLTI), the Gynecological Cancer Group Singapore (GCGS) and the Gynecologic Oncology Trial and Investigation Consortium (GOTIC).
Downloadable slides accompany this e-learning for your own use.
This educational programme is supported by an Independent Medical Education Grant from AstraZeneca